Vascular Endothelial Growth Factor Inhibition

Vascular endothelial growth factor inhibition prevents angiogenesis through receptor antagonism reducing tumour blood supply. Monoclonal antibody bevacizumab binds circulating VEGF. Small molecule tyrosine kinase inhibitors block VEGF receptor signalling. Angiogenesis reduction starves tumours limiting growth. Resistance mechanisms including alternative angiogenic pathway activation warrant investigation.

Regulatory submissions justify anti-angiogenesis mechanism. Clinical outcomes demonstrate efficacy over monotherapy. Adverse effects including hypertension warrant monitoring. Post-approval surveillance identifies resistance patterns. Emerging mechanisms overcome resistance.